1. Home
  2. HRMY vs HUN Comparison

HRMY vs HUN Comparison

Compare HRMY & HUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$35.24

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Huntsman Corporation

HUN

Huntsman Corporation

HOLD

Current Price

$10.39

Market Cap

1.8B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
HUN
Founded
2017
1970
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2020
2005

Fundamental Metrics

Financial Performance
Metric
HRMY
HUN
Price
$35.24
$10.39
Analyst Decision
Strong Buy
Hold
Analyst Count
9
11
Target Price
$50.56
$10.00
AVG Volume (30 Days)
934.4K
6.1M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
9.92%
EPS Growth
50.44
N/A
EPS
3.17
N/A
Revenue
$825,944,000.00
$5,780,000,000.00
Revenue This Year
$20.68
N/A
Revenue Next Year
$15.93
$4.44
P/E Ratio
$11.14
N/A
Revenue Growth
21.13
N/A
52 Week Low
$25.52
$7.30
52 Week High
$40.93
$20.94

Technical Indicators

Market Signals
Indicator
HRMY
HUN
Relative Strength Index (RSI) 71.09 70.22
Support Level $32.77 $8.04
Resistance Level $36.20 $8.97
Average True Range (ATR) 1.11 0.47
MACD 0.17 0.25
Stochastic Oscillator 81.04 98.75

Price Performance

Historical Comparison
HRMY
HUN

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About HUN Huntsman Corporation

Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. Its product portfolio comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, among others. Its operating segments are Polyurethanes, Performance Products, and Materials. It derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.

Share on Social Networks: